Skip to main content
. 2007 Mar;3(1):133–148. doi: 10.2147/tcrm.2007.3.1.133

Figure 2.

Figure 2

Results from the PREMIER study. (a) American College of Rheumatology 50 response at Years 1 and 2. aP<0.001 for adalimumab plus methotrexate (MTX) vs MTX alone and adalimumab plus MTX vs adalimumab alone. (b) Mean change from baseline in total Sharp scores (TSS) over time. aP<0.001 for adalimumab plus MTX vs MTX alone and adalimumab alone. bP<0.001 for adalimumab plus MTX vs MTX alone and P=0.002 for adalimumab plus MTX vs adalimumab alone. cP<0.001 for adalimumab vs MTX alone. Copyright © 2006. Reproduced with permission from Breedveld FC, Weisman MH, Kavanaugh AF, et al; for the PREMIER investigators. 2006. The PREMIER Study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naïve patients with early, aggressive rheumatoid arthritis. Arthritis Rheum, 54:26-37.